Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 10/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070183 | 0.81 | CYP3A4 (0.43) | PTGESKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4211589 | 0.80 | MEN1 (0.66) | PTGESKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4205329 | 0.78 | PTGES (0.59) | PTGESKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4208410 | 0.76 | PTGES (0.64) | PTGESKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4213982 | 0.74 | PTGES (0.73) | PTGESKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL4211408 | 0.73 | POLB (0.61) | PTGESKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4215781 | 0.73 | TP53 (0.61) | PTGESALDH1A1MAPTPOLB | |
| SCHEMBL4210265 | 0.73 | ALDH1A1 (0.60) | PTGESKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4215219 | 0.72 | TSHR (0.69) | PTGESKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL4217085 | 0.72 | MAPT (0.55) | PTGESKMT2AMEN1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | PTGES 644/4885KMT2A 3419/4885MEN1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.